Quantifying Benefits and Risks of GLP-1–Receptor Agonists for Patients with Diabetes
The glucagon-like peptide-1 (GLP-1)–receptor agonist drugs, developed to treat patients with diabetes, also deliver many additional benefits. In a very
Related Articles
Does Tenecteplase Before Thrombectomy Benefit Patients with Large-Vessel Occlusion Stroke?
In trials involving patients with acute ischemic stroke, intravenous thrombolysis (IVT) given before endovascular thrombectomy (EVT) is a common
More Risks Associated with Anabolic Steroid Use
Anabolic steroid (AS) use is associated with excess risk for infertility, cardiovascular disease, mental illness, and risk-taking behaviors. In
Combining Empagliflozin and Finerenone in Patients with Diabetes and Albuminuria
To delay progression of diabetic kidney disease, guidelines recommend 3 drug classes for selected patients: (1) renin–angiotensin system inhibitors,
A Randomized Trial of Fluid Restriction Advice for Heart Failure
The evidence to support fluid restriction in the management of heart failure (HF) is thin, however intuitively appealing the practice might seem. In
Add Vitamin C to Oral Iron?
Iron deficiency is the most common cause of anemia in the world and is typically treated with oral iron. However, oral iron’s effectiveness can be
Does Risk-Reducing Surgery Benefit Young Breast Cancer Survivors with
For carriers of BRCA1 or BRCA2 mutations, we’ve long known that bilateral salpingo-oophorectomy (BSO) and bilateral mastectomy reduce cancer risk in
What Are the Most Common Causes of Postpartum Hemorrhage?
Postpartum hemorrhage (PPH) accounts for 1 in 4 maternal deaths globally and an estimated 11% of maternal mortality in the U.S. To quantify rates of
Is Metabolic Syndrome Associated with Young-Onset Dementia?
Because features of metabolic syndrome (MetS) like elevated waist circumference, blood pressure, glucose, and triglycerides lead to higher rates of
Interview with Dr. William Gradishar, Dr. Julia Rotow, and Dr. Michael Williams
NEJM Group’s Dr. Inas Abuali talked with three of the five oncologists who guided our ASCO 2025 coverage to find out their key takeaways from…
Amiloride for Patients with Resistant Hypertension?
In a 2015 trial, researchers showed that spironolactone was superior to doxazosin and bisoprolol as a second-line agent for lowering blood pressure